|
|
|
Insider
Information: |
Schwabe Stefan K.f. |
Relationship: |
Executive Vice Preside... |
City: |
Rockville |
State: |
MD |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
1 |
|
Direct
Shares |
2,772 |
|
Indirect Shares
|
0 |
|
|
Direct
Value |
$85,294 |
|
|
Indirect Value
|
$0 |
|
|
Total
Shares |
2,772 |
|
|
Total
Value |
$85,294 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
0
|
Stock
price went up :
|
0
|
0
|
Stock
price went down : |
0
|
0
|
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
Percentage
Gain/Loss : |
0.0%
|
0.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Supernus Pharmaceuticals Inc |
SUPN |
Executive Vice Preside... |
2020-12-21 |
2,772 |
2015-06-11 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
13 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 1 of 1
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
SUPN |
Supernus Pharmaceuticals ... |
Executive Vice President R&D |
|
2015-06-11 |
4 |
AS |
$16.32 |
$59,521 |
D/D |
(3,631) |
4,845 |
0 |
- |
|
SUPN |
Supernus Pharmaceuticals ... |
Executive Vice President R&D |
|
2015-06-12 |
4 |
AS |
$18.27 |
$37,472 |
D/D |
(2,051) |
2,794 |
0 |
- |
|
SUPN |
Supernus Pharmaceuticals ... |
Executive Vice President R&D |
|
2015-07-13 |
4 |
AS |
$19.23 |
$37,499 |
D/D |
(1,950) |
844 |
0 |
- |
|
SUPN |
Supernus Pharmaceuticals ... |
Executive Vice President R&D |
|
2015-07-13 |
4/A |
AS |
$19.23 |
$37,499 |
D/D |
(1,950) |
2,350 |
0 |
- |
|
SUPN |
Supernus Pharmaceuticals ... |
Executive Vice President R&D |
|
2015-07-28 |
4 |
AS |
$21.20 |
$49,827 |
D/D |
(2,350) |
0 |
0 |
- |
|
SUPN |
Supernus Pharmaceuticals ... |
Executive Vice President R&D |
|
2017-09-07 |
4 |
AS |
$46.59 |
$4,425,575 |
D/D |
(95,000) |
1,855 |
0 |
- |
|
SUPN |
Supernus Pharmaceuticals ... |
Executive Vice President R&D |
|
2017-09-07 |
4 |
OE |
$12.92 |
$1,227,400 |
D/D |
95,000 |
96,855 |
0 |
- |
|
SUPN |
Supernus Pharmaceuticals ... |
Executive VP R&D, CMO |
|
2018-06-18 |
4 |
OE |
$7.90 |
$527,600 |
D/D |
60,000 |
61,967 |
0 |
- |
|
SUPN |
Supernus Pharmaceuticals ... |
Executive VP R&D, CMO |
|
2018-06-18 |
4 |
AS |
$54.39 |
$3,263,352 |
D/D |
(60,000) |
1,967 |
0 |
- |
|
SUPN |
Supernus Pharmaceuticals ... |
Executive Vice President & CMO |
|
2020-12-14 |
4 |
AS |
$21.86 |
$1,173,264 |
D/D |
(53,653) |
2,772 |
0 |
- |
|
SUPN |
Supernus Pharmaceuticals ... |
Executive Vice President & CMO |
|
2020-12-14 |
4 |
OE |
$9.13 |
$503,916 |
D/D |
53,653 |
56,425 |
0 |
- |
|
SUPN |
Supernus Pharmaceuticals ... |
Executive Vice President & CMO |
|
2020-12-21 |
4 |
AS |
$22.10 |
$1,024,463 |
D/D |
(46,347) |
2,772 |
0 |
- |
|
SUPN |
Supernus Pharmaceuticals ... |
Executive Vice President & CMO |
|
2020-12-21 |
4 |
OE |
$12.98 |
$601,584 |
D/D |
46,347 |
49,119 |
0 |
- |
|
13 Records found
|
1
|
Page 1 of 1 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|